⚗️ GLP-1 USER PROFILE
Semaglutide and tirzepatide suppress appetite by 30–40%. They have no mechanism for protecting muscle, replacing B12, maintaining zinc, or preventing bone loss during rapid weight change.
The Rebuild profile layers three things: universal deficiency correction, GLP-1 specific hormonal support, and your existing condition's interaction with the drug.
THE THREE LAYERS
01
Nutritional deficits
Eating 30–40% fewer calories means proportionally fewer vitamins and minerals — while your body is working harder to rebuild. Protein, B12, iron, zinc, D3, and thiamine all drop predictably.
02
GLP-1 hormonal effects
The drug is actively shifting your hormone profile: increasing testosterone (through insulin/aromatase pathways), modulating cortisol (via hypothalamic GLP-1 receptors), and resolving sleep apnea — all of which cascade into your existing hormonal condition.
03
Condition interactions
If you have low testosterone, high cortisol, sleep apnea, or cardiovascular risk — GLP-1 interactions with each one are meaningfully different. The protocol adapts to your specific combination.
THE MUSCLE PROBLEM
“In trials without resistance training, 25–40% of total weight lost on semaglutide is lean mass, not fat — a ratio that worsens with age.”
NEJM / Lancet Diabetes analyses of STEP trial body composition substudies, 2024
GLP-1 drugs suppress appetite indiscriminately — the body has no mechanism to preferentially protect muscle tissue during rapid weight loss without external intervention. Essential amino acids (especially leucine) and creatine shift the ratio. This is the most important intervention for any man on a GLP-1.
THE REBUILD STACK
GLP-1 drugs cause 25–40% of total weight loss to come from lean muscle mass, not fat — without deliberate protein support. EAAs, especially leucine, activate mTOR signaling to preserve muscle protein synthesis even in a significant caloric deficit. This is the highest-priority supplement for any man on semaglutide or tirzepatide.
Multiple RCTs confirm creatine specifically reduces lean mass loss during caloric restriction — an effect independent of its training performance benefits. GLP-1 users lose more muscle than fat-only dieters; creatine shifts this ratio. Also: creatine supports phosphocreatine resynthesis during resistance training, which is the primary tool for muscle preservation on GLP-1s.
GLP-1 drugs suppress gastric acid secretion. B12 absorption depends on intrinsic factor, which requires stomach acid to release from food proteins. Sublingual administration bypasses the stomach entirely. B12 deficiency presents as fatigue, brain fog, tingling hands and feet — symptoms routinely misattributed to the medication. In men, low B12 also impairs mitochondrial function in Leydig cells, impairing testosterone synthesis.
Zinc is a direct cofactor in testosterone synthesis at the Leydig cell level, and GLP-1 drugs reduce dietary zinc intake substantially. This is a compounding risk: GLP-1 drugs are simultaneously restoring testosterone through metabolic improvement while potentially undermining it through zinc deficiency. Bisglycinate avoids the copper displacement seen with high-dose zinc sulfate.
Rapid weight loss releases fat-stored vitamin D from adipose tissue — but also depletes ongoing fat-soluble vitamin reserves. Vitamin D receptors are expressed in Leydig cells; D deficiency directly impairs testosterone synthesis. K2 is paired because rapid weight loss accelerates bone turnover, and K2 directs calcium to bone matrix rather than vascular tissue. Both are critical during GLP-1-driven weight loss.
Two complementary mechanisms: EPA reduces SHBG, increasing free testosterone bioavailability — particularly relevant as GLP-1 drugs increase total SHBG (which can partially offset the T increase). Separately, GLP-1 drugs have proven cardiovascular benefit (SELECT trial: 20% MACE reduction); omega-3 works on the same vascular endothelial and anti-inflammatory pathways and is additive.
Reduced food intake on GLP-1s drops dietary magnesium substantially. Magnesium runs three systems simultaneously relevant to men on GLP-1s: insulin sensitivity (works on the same pathway as the drug), sleep architecture (supports SWS where 70% of testosterone is synthesized), and cortisol regulation (magnesium is a rate-limiting cofactor for cortisol metabolism). GI-gentle glycinate form is important given GLP-1 gut side effects.
A safety supplement, not just optimization. Wernicke's encephalopathy — a severe neurological thiamine deficiency — is documented in bariatric surgery patients and has been reported in GLP-1 users with severe nausea or vomiting. B1 is rapidly depleted when caloric intake drops steeply and GI absorption is impaired. Symptoms (confusion, eye movement problems, unsteady gait) can be subtle initially. At 100mg it is completely safe; untreated deficiency is not.
YOUR EXISTING CONDITION + GLP-1
GLP-1 drugs increase testosterone in most men with metabolic hypogonadism — 2025 data shows mean +127 ng/dL, 71% normalization rate without TRT. However, GLP-1 also increases SHBG, which can partially offset free T gains. Zinc and magnesium in The Rebuild stack specifically target SHBG reduction. If you are on TRT, your prescriber may need to reduce your dose.
GLP-1 receptors in the hypothalamic paraventricular nucleus suppress CRH release, reducing the cortisol stress response. This is additive with ashwagandha (KSM-66). However, the appetite suppression from GLP-1 can paradoxically increase cortisol if men skip meals and blood glucose drops — the body reads hypoglycemia as a stress signal. Consistent meal timing matters more on GLP-1s than off them.
This is the highest-risk combination. GLP-1 drugs dramatically impair muscle mass preservation without structured resistance training and adequate protein. Athletes on GLP-1s who are not deliberately protecting lean mass via EAAs, creatine, and resistance training can lose significant strength. The appetite suppression also makes hitting protein targets (1.6–2.2g/kg) much harder. WADA bans peptide GH secretagogues (ipamorelin, CJC-1295) — not semaglutide/tirzepatide themselves, which are unscheduled.
⚠ Prioritize resistance training and protein tracking — these are non-optional on GLP-1 + athletic performance.
GLP-1 drugs produce 30–40% improvement in sleep apnea severity (SURMOUNT-OSA trial, tirzepatide 2024) — and may fully resolve it in up to 51% of cases. If your sleep apnea is improving, your CPAP pressure settings may become inappropriate (too high), causing new fragmentation. Revisit your sleep study if you've lost significant weight. Nocturnal testosterone synthesis will improve as sleep apnea resolves — a meaningful T boost without any additional supplementation.
⚠ If you use CPAP: schedule a pressure re-evaluation after every 20 lbs lost.
GLP-1 drugs have the strongest cardiovascular evidence of any non-statin intervention: SELECT trial (2023, semaglutide, non-diabetic) showed 20% reduction in MACE. Direct GLP-1 receptors on cardiomyocytes improve myocardial glucose utilization. The Rebuild's omega-3 and magnesium work on complementary pathways. If you're on statins, be aware that rapid weight loss can occasionally require statin dose adjustment as LDL shifts.
GLP-1 receptors in the prefrontal cortex and nucleus accumbens modulate dopamine reuptake — overlapping circuitry with ADHD and with stimulant medications. Some men on GLP-1 + stimulants report their effective stimulant dose shifting (higher or lower). GLP-1's appetite suppression also reduces the food-reward hypersensitivity that is common in ADHD. Monitor for changes in stimulant effectiveness and discuss adjustments with your prescriber.
⚠ If on Adderall or Vyvanse: pay attention to appetite suppression compounding — you may need to actively schedule meals.
FOUNDING MEMBERS
Early access · Founding member pricing · Your protocol in minutes
QUESTIONS